Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study.
Wagner NB, Knierim SM, Luttermann F, Metzler G, Yazdi AS, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler TK, Forchhammer S, Flatz L. Wagner NB, et al. Among authors: bauer j. J Am Acad Dermatol. 2024 Apr;90(4):739-748. doi: 10.1016/j.jaad.2023.11.040. Epub 2023 Dec 1. J Am Acad Dermatol. 2024. PMID: 38043594 Free article.
Molecular genetic classification of difficult melanocytic tumors.
Metzler G, Eigentler TK, Held L, Kind P, Hantschke M, Garbe C, Bauer J. Metzler G, et al. Among authors: bauer j. J Dtsch Dermatol Ges. 2013 May;11 Suppl 4:11-8. doi: 10.1111/ddg.12085_supp. J Dtsch Dermatol Ges. 2013. PMID: 23721635 Review. No abstract available.
Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour.
Weide B, Faller C, Elsässer M, Büttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Meier F, Garbe C. Weide B, et al. Among authors: bauer j. PLoS One. 2013 Jun 25;8(6):e66953. doi: 10.1371/journal.pone.0066953. Print 2013. PLoS One. 2013. PMID: 23825594 Free PMC article.
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F. Niessner H, et al. Among authors: bauer j. Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3. Cancer Med. 2013. PMID: 24133630 Free PMC article.
Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas.
Gassenmaier M, Hahn M, Metzler G, Bauer J, Yazdi AS, Keim U, Garbe C, Wagner NB, Forchhammer S. Gassenmaier M, et al. Among authors: bauer j. Cancers (Basel). 2021 Jul 31;13(15):3864. doi: 10.3390/cancers13153864. Cancers (Basel). 2021. PMID: 34359765 Free PMC article.
4,499 results